The short version
PCOS is one of the most common hormonal conditions in women of reproductive age, and one of the most under-supported when it comes to weight management. The difficulty many women experience in managing their weight with PCOS is biological in origin, driven by insulin resistance, elevated androgens, and hormonal disruption that standard dietary advice was not designed to address. This article covers what PCOS is, why it makes weight management harder, and what the evidence actually supports across diet, exercise, mental health, sleep, fertility, and treatment options.
What Is PCOS?
Polycystic ovary syndrome is a common endocrine disorder affecting women of reproductive age, with a worldwide prevalence of between 6 and 20 per cent depending on the diagnostic criteria used (Zhao et al., 2023). In Australia, it is estimated to affect approximately one in eight to one in ten women, making it one of the most prevalent hormonal conditions seen in general practice and specialist settings.
The name is somewhat misleading. PCOS does not require the presence of cysts. What appear on ultrasound as cysts are typically small immature follicles, and their presence is only one of three possible diagnostic criteria. A diagnosis requires two of the following three findings: irregular or absent ovulation (reflected in irregular or absent periods), elevated androgen levels (measured in blood or reflected in symptoms such as acne, excess facial and body hair, or scalp hair thinning), and polycystic ovaries on ultrasound. A woman can have a confirmed PCOS diagnosis without ever having had an ultrasound.
It is also worth naming what PCOS is not. It is not simply a gynaecological condition. It is a systemic metabolic and hormonal disorder with implications for weight, cardiovascular health, mental health, and long-term diabetes risk. Treating it as a purely reproductive concern, which has historically been common in clinical settings, misses a significant part of what women with PCOS are actually managing.
What Causes PCOS?
The precise cause of PCOS is not fully understood, but the two most consistently identified pathophysiological drivers are insulin resistance and elevated androgens, and the relationship between them is circular.
Insulin resistance, which is present in an estimated 50 to 80 per cent of women with PCOS, causes the body to produce higher levels of insulin to manage blood sugar (Teede et al., 2010). That excess insulin stimulates the ovaries to produce more androgens, particularly testosterone. Elevated androgens in turn disrupt ovulation, reduce sex hormone-binding globulin (which normally keeps androgens in check), and contribute to further insulin resistance. The two systems reinforce each other.
Genetics plays a meaningful role. PCOS clusters in families, and daughters of women with PCOS show early signs of hormonal and metabolic disruption from childhood. Environment, including body weight, diet quality, and physical activity, interacts with genetic predisposition to influence severity. PCOS exists on a spectrum: some women have mild, largely asymptomatic presentations, while others carry a significant hormonal and metabolic burden. The same diagnosis can look very different in two different people.
What Are The Symptoms Of PCOS?
PCOS symptoms vary considerably between individuals, which is one of the reasons it is frequently underdiagnosed or diagnosed late. The average time from first symptoms to diagnosis is reported to be several years in many studies, and a significant proportion of women with PCOS remain undiagnosed.
The most commonly reported symptoms include irregular, infrequent, or absent menstrual periods, difficulty losing weight or unexplained weight gain particularly around the abdomen, acne that is often hormonal in pattern (jawline, chin, neck), excess hair growth on the face, chest, or abdomen (hirsutism), scalp hair thinning or loss, skin tags, and darkened patches of skin in areas such as the neck or underarms (acanthosis nigricans, a marker of insulin resistance). Fatigue, mood changes, and difficulty concentrating are also commonly reported but less frequently linked to PCOS in clinical conversations.
It is worth noting that PCOS can present in lean women as well as those with overweight or obesity, though it is occassionally assumed to be a condition only affecting women who are carrying excess weight. Insulin resistance can be present in the absence of obesity, and all of the hormonal features of PCOS can occur across the weight spectrum.
Why Is Weight Loss Harder With PCOS?
This is the question I am asked most frequently by women with PCOS in clinical practice, and it deserves a thorough answer because the biological reality is often poorly communicated.
Insulin resistance is the central mechanism. When the body does not respond efficiently to insulin, it produces more of it to manage blood sugar. Chronically elevated insulin promotes fat storage, particularly in the abdominal region, and suppresses the body’s ability to access stored fat for energy. This means that even a modest caloric deficit may not produce the fat loss that would be expected in a person without insulin resistance, because the metabolic environment is actively working against it.
Elevated androgens further compound this. In women, elevated testosterone and related hormones promote an android pattern of fat distribution, meaning fat accumulates preferentially around the abdomen rather than in the hips and thighs. This is the same pattern more commonly seen in men, and it includes visceral fat, the metabolically active fat stored around the internal organs that carries its own distinct health risks.
Appetite regulation is also affected. Insulin resistance disrupts the normal signalling of leptin and ghrelin, the hormones that communicate hunger and satiety to the brain. Women with PCOS often describe persistent hunger even after eating, cravings for carbohydrate-dense foods, and difficulty feeling satisfied from meals. These are not character failings. They are the downstream effects of a hormonal system that is not functioning in the way it is designed to.
If you have been told that you simply need to try harder, or that the principles of weight loss are the same for everyone, that advice did not account for the specific biological context of PCOS. It is worth understanding why the standard framing is incomplete before concluding that the problem is you. Our Shame And Obesity article addresses this framing directly.
PCOS And Belly Fat: What Is Actually Happening
Abdominal weight gain is one of the most distressing and least explained aspects of PCOS for many women. Understanding the mechanism helps, even if it does not immediately solve it.
The visceral fat that accumulates in PCOS is not simply subcutaneous fat sitting beneath the skin. It is fat stored inside the abdominal cavity, around the liver, pancreas, and other organs. Visceral fat is metabolically active: it releases inflammatory molecules and free fatty acids directly into the portal circulation, contributing to insulin resistance, elevated triglycerides, and increased cardiovascular risk. This is one of the reasons that PCOS carries long-term risks for type 2 diabetes and heart disease that go beyond the visible symptoms.
Measuring waist circumference and tracking body composition over time gives a more clinically meaningful picture of what is happening in PCOS than scale weight alone. A woman with PCOS can be at a medically normal weight while carrying a disproportionate amount of visceral fat, and this will not be captured by the scale or BMI. Body composition assessment, which measures fat mass, lean mass, and visceral fat estimates over time, is a valuable part of monitoring in this context.
We cover the value of body composition monitoring over scale weight in our Body Composition Scans page.
PCOS And Diet: What The Evidence Actually Supports
There is no single PCOS diet with strong evidence behind it, and I want to be clear about that upfront rather than presenting one dietary pattern as the definitive answer. The research on specific dietary approaches in PCOS is limited by small sample sizes and short follow-up periods. What the broader evidence does support, consistently, is eating in a way that reduces the insulin load on the body and supports blood sugar stability.
Protein is the macronutrient with the strongest evidence for supporting satiety and insulin sensitivity in PCOS. Adequate protein at each meal helps buffer the blood sugar response to carbohydrates, reduces the insulin spike that follows eating, and supports lean muscle mass, which further improves insulin sensitivity over time. The evidence points toward a minimum of around 25 to 30 grams of protein per meal, which is considerably more than most women are routinely eating.
Fibre from vegetables, legumes, and wholegrains supports blood sugar stability through slower digestion and positive effects on the gut microbiome. Healthy fats from sources such as olive oil, avocado, nuts, and oily fish have anti-inflammatory effects that are particularly relevant in PCOS given the chronic low-grade inflammation associated with the condition. Refined carbohydrates and added sugars produce the fastest and largest insulin responses and are the most useful target for reduction in an insulin-resistant metabolic environment.
Meal timing also matters more in PCOS than is commonly recognised. Skipping breakfast and eating the majority of calories in the evening, a pattern many women fall into, tends to worsen insulin sensitivity and blood sugar regulation across the day. Distributing food intake more evenly across the day, with a substantial and protein-containing morning meal, generally produces better metabolic outcomes than the same total calorie intake concentrated later.
I want to be careful here not to imply that eating is the only lever, or that the difficulty with diet in PCOS is simply a matter of not knowing the right approach. The insulin-driven hunger and carbohydrate craving that many women with PCOS experience makes it genuinely harder to maintain the eating patterns that would best support their condition. Acknowledgement of that difficulty is part of honest clinical care.
PCOS And Exercise: More Than Calorie Burning
Exercise has a direct and clinically meaningful effect on insulin sensitivity in PCOS that goes well beyond its contribution to energy expenditure. Muscle contraction promotes glucose uptake through pathways that are independent of insulin, meaning that resistance exercise and aerobic activity can improve blood sugar regulation even in an insulin-resistant state.
Resistance training, specifically the kind that challenges muscle through progressively increasing load, has the strongest evidence for improving body composition in PCOS. It builds and preserves lean muscle mass, which is metabolically active tissue that improves insulin sensitivity at rest. Two or more sessions of resistance exercise per week is a consistent recommendation in the evidence base for PCOS management.
Aerobic exercise, including brisk walking, cycling, and swimming, improves cardiovascular fitness and contributes to insulin sensitivity through different mechanisms. Both forms of exercise are valuable and they complement each other. The most effective exercise programme for PCOS is one that combines progressive resistance work with regular moderate aerobic activity, and one that is consistent over time rather than intensive in short bursts.
One practical note: high-intensity training in the context of poor sleep, elevated cortisol, and an already stressed hormonal system can occasionally worsen inflammation and fatigue in PCOS. Starting at a moderate intensity and building progressively tends to be more sustainable than pushing immediately into very high-intensity protocols, particularly in women who are newly diagnosed or have been sedentary for some time. A clinical exercise physiologist who understands the PCOS context is a useful part of the support team.
PCOS And Mental Health
The psychological burden of PCOS is substantial and consistently underreported in clinical consultations. Rates of anxiety, depression, and impaired quality of life are significantly higher in women with PCOS than in the general population. Body image concerns, the visible symptoms of hyperandrogenism such as acne and hair changes, the experience of unexplained weight gain, the fertility implications of the condition, and the history of dismissal or delayed diagnosis that many women carry all contribute to this.
There is also a direct biological contribution. Hormonal fluctuations, particularly the effects of elevated androgens and insulin dysregulation on neurotransmitter systems, may have direct mood effects independent of the psychosocial burden. Sleep disruption, which is common in PCOS through multiple mechanisms, further compounds mood instability and cognitive function.
In clinical practice, I ask about mood, sleep, and quality of life as part of every assessment for PCOS. The mental health component is not secondary to the physical management. For many women, it is what matters most, and a treatment approach that improves metabolic markers while leaving a person feeling demoralised and exhausted is not a complete clinical success.
The connection between shame, chronic conditions, and clinical outcomes is explored in our Shame And Obesity article. Much of what applies to obesity-related shame applies equally to the experience of women with PCOS who have been dismissed, misdiagnosed, or told that their symptoms are within normal range.
PCOS And Sleep
Sleep disruption is more common in women with PCOS than in age-matched controls, and it operates through several mechanisms. Sleep apnoea, which occurs at higher rates in PCOS independent of body weight, directly disrupts sleep architecture. Insulin resistance and elevated cortisol affect the body’s natural sleep-wake rhythm. Anxiety and mood disturbance, which are more prevalent in PCOS, are significant contributors to difficulty initiating and maintaining sleep.
The consequences of disrupted sleep are particularly relevant in PCOS because poor sleep directly worsens the two central pathophysiological features of the condition. Sleep restriction raises ghrelin and suppresses leptin, driving increased appetite and cravings for high-energy foods. It also worsens insulin resistance, creating a self-reinforcing cycle in which poor sleep makes the metabolic features of PCOS harder to manage, and the hormonal disruption of PCOS makes sleep harder to achieve.
Assessing sleep quality is a meaningful clinical step in PCOS management. Where sleep apnoea is suspected, investigation and treatment can produce significant improvements in both sleep quality and metabolic function. Sleep hygiene, and where indicated, pharmacological support for sleep, should be part of the treatment picture rather than an afterthought.
PCOS And Fertility
PCOS is one of the most common causes of irregular ovulation and a leading contributing factor to subfertility in women of reproductive age. Irregular or absent ovulation means irregular or absent opportunities for conception, and women with PCOS may go months between ovulatory cycles.
The evidence on the relationship between weight management and fertility in PCOS is consistently encouraging. Even modest weight loss of five per cent of body weight has been shown to improve insulin sensitivity, reduce androgen levels, restore ovulation, and improve the regularity of menstrual cycles in women with PCOS and overweight or obesity. These improvements occur through the insulin-androgen pathway: when insulin resistance improves, androgen production from the ovaries decreases, and ovulation becomes more likely.
For women pursuing conception, a clinical approach that addresses the metabolic features of PCOS alongside specific fertility support is more likely to produce results than fertility treatment in isolation. The broader hormonal and metabolic environment matters for both conception rates and pregnancy outcomes. Women with PCOS who are overweight have higher rates of gestational diabetes, hypertension, and miscarriage, and supporting metabolic health before conception reduces these risks.
It is important to note that fertility support in PCOS is a specialist area that requires individual clinical assessment. The approach that is appropriate for one woman will not be appropriate for another, and decisions about timing, treatment modality, and goals should be made in consultation with a clinician who understands the full picture.
PCOS And Long-Term Health Risks
PCOS is a lifelong condition with health implications that extend well beyond the reproductive years. Understanding the long-term risks is part of understanding why managing the condition actively, rather than waiting until symptoms become severe, matters clinically.
The most significant long-term risk is type 2 diabetes. Women with PCOS have substantially elevated rates of impaired glucose tolerance and type 2 diabetes compared to age and weight-matched controls, and this risk persists after menopause. Regular metabolic screening, including fasting glucose and HbA1c, should be a routine part of PCOS monitoring rather than an optional extra.
Cardiovascular risk is also elevated in PCOS, through the combined effects of insulin resistance, dyslipidaemia, hypertension, and chronic inflammation. The pattern of visceral fat accumulation described earlier contributes directly to cardiovascular risk factors. Blood pressure, cholesterol, and markers of inflammation are worth monitoring as part of the broader clinical picture.
Endometrial health requires attention in women with irregular periods. Infrequent ovulation means the endometrium is exposed to oestrogen without regular progesterone counterbalance, which over time increases the risk of endometrial hyperplasia. Women with PCOS who have fewer than four periods per year should be assessed for this, and strategies to induce regular shedding of the endometrium are part of clinical management.
PCOS Treatment: What The Options Look Like
PCOS does not have a single treatment pathway because the condition presents differently and the priorities differ between individuals. A woman whose primary concern is fertility has different clinical needs to a woman whose priorities are weight management, symptom control, or long-term metabolic risk reduction. Good PCOS care begins with a thorough clinical assessment that establishes what is actually driving symptoms and what the individual’s priorities are.
Lifestyle Intervention
Lifestyle intervention, encompassing dietary change, physical activity, and where relevant sleep and stress management, is first-line treatment for PCOS in women with overweight or obesity. The evidence is consistent that even modest improvements in weight and metabolic function produce meaningful changes in hormonal profiles, menstrual regularity, and symptom severity. The clinical goal is not necessarily reaching a particular weight. It is improving insulin sensitivity and reducing androgen excess, and these can occur with relatively small changes in weight when the approach is well-targeted.
Metformin
Metformin is an insulin-sensitising medication that is widely used in PCOS management. It improves the body’s response to insulin, which reduces the compensatory hyperinsulinaemia that drives androgen excess. It can improve menstrual regularity, reduce androgen levels, and in some cases support modest weight loss. It is not a weight loss medication in its own right, but it addresses one of the central pathophysiological mechanisms of the condition. Metformin is generally well-tolerated though gastrointestinal side effects are common, particularly early in treatment, and doses are typically increased gradually.
Hormonal Contraceptives
Hormonal contraceptives, most commonly the combined oral contraceptive pill, are frequently used in PCOS to regulate menstrual cycles, reduce androgen levels, and manage symptoms such as acne and hirsutism. They do not address the underlying insulin resistance and are not suitable for women who are trying to conceive. For women whose primary concerns are symptom management and menstrual regularity rather than fertility, they can be clinically useful and are generally well tolerated.
GLP-1 Receptor Agonists
GLP-1 receptor agonists are an emerging area of clinical interest in PCOS, and the emerging evidence is promising. These medications improve insulin sensitivity, reduce appetite through effects on hypothalamic appetite regulation, and produce meaningful weight loss in women with insulin resistance. A meta-analysis of eleven randomised controlled trials involving 840 women with PCOS found that GLP-1 receptor agonists were associated with improvements in menstrual regularity, natural pregnancy rates, insulin resistance, and androgen markers compared to control groups (Zhou et al., 2023). The medications are not specifically approved for PCOS in Australia, and the evidence base is still developing. Individual suitability requires careful clinical assessment and should not be assumed. Where insulin resistance and weight management are clinically significant features of a woman’s PCOS, they may form part of a treatment discussion with a clinician experienced in obesity medicine.
Multidisciplinary Support
The strongest outcomes in PCOS management come from a multidisciplinary approach that addresses the hormonal, metabolic, nutritional, and psychological dimensions of the condition simultaneously. A doctor experienced in obesity medicine and PCOS, a dietitian who understands the specific nutritional considerations, an exercise physiologist who can develop a programme calibrated to the metabolic context, and psychological or coaching support for the significant mood and quality of life burden the condition carries, together produce better results than any single intervention in isolation. For a condition as multifaceted as PCOS, this is not a luxury. It is what evidence-based care looks like.
How Much Does Weight Loss Help PCOS?
The evidence on this is one of the more encouraging findings in PCOS research. Weight loss does not need to be large to produce meaningful clinical benefit. Studies consistently show that a five per cent reduction in body weight in women with PCOS and overweight or obesity produces measurable improvements in insulin sensitivity, reductions in circulating androgen levels, improvements in menstrual regularity, and reductions in the hormonal and metabolic features of the condition.
These improvements are real and they occurs through the insulin pathway: as weight and particularly visceral fat decreases, insulin resistance improves, androgen production from the ovaries falls, and the cascade of hormonal disruption that characterises PCOS begins to moderate. For women pursuing fertility, these improvements may be sufficient to restore ovulation.
The implication of this is important for clinical communication. The goal in weight management for PCOS is not necessarily a specific target weight or a large total loss. It is metabolic improvement, and that can begin to occur with relatively modest changes. A five per cent loss in a woman weighing 90 kilograms is 4.5 kilograms. That is a clinically meaningful amount that sits within reach for most people with the right support, and the health impact of achieving it in PCOS can be substantial.
Getting A Diagnosis
Many women with PCOS go undiagnosed or are diagnosed late, sometimes after years of managing symptoms that were not connected to the underlying condition. The path to diagnosis typically begins with a GP appointment to discuss symptoms, followed by blood tests to assess hormone levels (including LH, FSH, testosterone, SHBG, prolactin, and thyroid function), metabolic markers (fasting glucose, insulin, lipid profile), and in many cases a pelvic ultrasound.
Diagnosis is made on the Rotterdam criteria, requiring two of the three features described earlier: irregular ovulation, elevated androgens, and polycystic ovaries on ultrasound. Because no single test confirms PCOS, and because other conditions can produce similar symptoms, the diagnosis is clinical and requires a clinician who takes the full picture into account.
If you have been dismissed with the explanation that your symptoms are normal or that your results are borderline, it is reasonable to seek a second opinion or to ask for a referral to a specialist in reproductive endocrinology or obesity medicine. Many women with PCOS have had the experience of being told their symptoms are within range when a more thorough assessment would have revealed a clinically significant pattern. That experience is common enough to be worth naming.
This article is general information only and not personal medical advice. Obesity assessment and treatment decisions should be made with a qualified health professional after individual clinical assessment. Not all treatments are suitable for every person.
Looking Forward
PCOS is a condition that has been underfunded in research, underserved in clinical training, and too often reduced to its most visible features in the clinical room. Women with PCOS frequently arrive having spent years managing significant symptoms without an adequate explanation of what is driving them, and without support that addresses the full biological picture.
That is changing. The understanding of PCOS as a systemic metabolic and hormonal condition, rather than simply a reproductive one, is increasingly reflected in clinical guidelines and in the treatments available. The evidence on insulin resistance as a central driver means that interventions targeting that mechanism, whether through lifestyle, medication, or a combination of both, can produce meaningful improvements across the full range of PCOS features.
If PCOS is part of your clinical picture and weight management is something you have been finding genuinely difficult, a clinical assessment that accounts for the specific metabolic context of the condition is the starting point. Individual suitability for any treatment requires that assessment. That is a conversation we are ready to have at Alevia.
Evidence Notes
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023). Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. Journal of Ovarian Research, 16(1), 9. https://doi.org/10.1186/s13048-022-01091-0
Xu, Y., & Qiao, J. (2022). Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): a review of literature. Journal of Healthcare Engineering, 2022, 9240569. https://doi.org/10.1155/2022/9240569
Teede, H., Deeks, A., & Moran, L. (2010). Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine, 8, 41. https://doi.org/10.1186/1741-7015-8-41
Zhou, L., Qu, H., Yang, L., & Shou, L. (2023). Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocrine Disorders, 23, 245. https://doi.org/10.1186/s12902-023-01500-5
Book your appointment
